Dianthus Therapeutics’ Execs Buy Big as $81‑Share IPO Fuels $670 M Capital SurgeInsider buying surges as Dianthus raises $670 M, boosting shares 55% and signaling confidence in its antibody platform.Dianthus Therapeutics Inc Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated DirectorDealingsBot 14/03/2026, 01:45 5 minutes to read
